Physician profile
Shalin Shah
NPI 1265591804
$12,886.38
in general payments reported to CMS, 2019-2025
74 companies · $2,002 in 2025
The $2,002 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,046 · 2020: $557 · 2021: $531 · 2022: $2,058 · 2023: $2,238 · 2024: $3,455 · 2025: $2,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,769 · Travel and Lodging: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,768.81 |
| Travel and Lodging | $926.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,471.21 | 2019-2024 | |
| Pfizer INC. | $1,028.03 | 2019-2025 | |
| Biosense Webster, INC. | $1,008.56 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $946.14 | 2019-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $642.11 | 2019-2025 | Trodelvy |
| Janssen Biotech, INC. | $553.87 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Genentech USA, INC. | $483.67 | 2019-2024 | Tecentriq, Alecensa, Polivy |
| Merck Sharp & Dohme LLC | $446.46 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Boston Scientific Corporation | $412.29 | 2021-2025 | Watchman Access System, Farapulse, Watchman Flx |
| Abbvie INC. | $405.90 | 2019-2025 | Venclexta |
| Celgene Corporation | $373.50 | 2019-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $348.76 | 2019-2023 | Tagrisso, Lynparza |
| Daiichi Sankyo INC. | $333.33 | 2022-2025 | Enhertu, Datroway |
| Genzyme Corporation | $316.46 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.25 | 2020-2025 | Fruzaqla, Alunbrig |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalin Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.